Cystic fibrosis-related diabetes and lung disease: an update.
Bernadette J PrenticeAdam JaffeShihab HameedCharles F VergeShafagh A WatersJohn WidgerPublished in: European respiratory review : an official journal of the European Respiratory Society (2021)
The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung function and early mortality. This review highlights the many factors contributing to the clinical decline seen in patients diagnosed with CFRD, highlighting the important role of nutrition, the direct effect of hyperglycaemia on the lungs, the immunomodulatory effects of high glucose levels and the potential role of genetic modifiers in CFRD.
Keyphrases
- cystic fibrosis
- lung function
- end stage renal disease
- newly diagnosed
- pseudomonas aeruginosa
- ejection fraction
- type diabetes
- cardiovascular disease
- chronic obstructive pulmonary disease
- chronic kidney disease
- peritoneal dialysis
- pulmonary hypertension
- glycemic control
- risk factors
- patient reported outcomes
- coronary artery disease
- skeletal muscle
- climate change